{"@type": "dcat:Dataset", "accessLevel": "public", "bureauCode": ["009:20"], "contactPoint": {"@type": "vcard:Contact", "fn": "VaxView Team", "hasEmail": "mailto:VaxView@cdc.gov"}, "description": "Monthly Cumulative Number and Percent of Children <20 Months Who Received Nirsevimab by Age Group and Jurisdiction\n\n\u2022 Estimated nirsevimab coverage for children 0-19 months is assessed through U.S. jurisdictions\u2019 Immunization Information Systems (IIS) data, submitted from jurisdictions to CDC monthly in aggregate by age group. \n\n\u2022 Starting in July 2023, the CDC recommended the RSV vaccine to protect against serious illness from RSV. (https://www.cdc.gov/respiratory-viruses/whats-new/rsv-update-2023-09-22.html)\n\u2003", "distribution": [{"@type": "dcat:Distribution", "downloadURL": "https://data.cdc.gov/api/v3/views/ku7p-zn4c/export.csv?accessType=DOWNLOAD", "mediaType": "text/csv"}, {"@type": "dcat:Distribution", "downloadURL": "https://data.cdc.gov/api/v3/views/ku7p-zn4c/query.json?accessType=DOWNLOAD", "mediaType": "application/json"}, {"@type": "dcat:Distribution", "downloadURL": "https://data.cdc.gov/api/v3/views/ku7p-zn4c/query.xml?accessType=DOWNLOAD", "mediaType": "application/xml"}], "identifier": "https://data.cdc.gov/api/views/ku7p-zn4c", "issued": "2024-02-13", "keyword": ["iis", "immunization information system", "rsv vaccination"], "landingPage": "https://www.cdc.gov/vaccines/vaxview/index.html", "language": ["English"], "license": "https://www.usa.gov/government-works", "modified": "2026-08-03", "programCode": ["009:020"], "publisher": {"@type": "org:Organization", "name": "Centers for Disease Control and Prevention"}, "spatial": "Jurisdictions - States, District of Columbia, Islands, and US cities", "theme": ["Vaccinations"], "title": "Monthly Cumulative Number and Percent of Children <20 Months Who Received Nirsevimab by Age Group and Jurisdiction, United States"}